Cargando…

Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice

BACKGROUND: Vaccines that block human-to-mosquito Plasmodium transmission are needed for malaria eradication, and clinical trials have targeted zygote antigen Pfs25 for decades. We reported that a Pfs25 protein-protein conjugate vaccine formulated in alum adjuvant induced serum functional activity i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Healy, Sara A., Anderson, Charles, Swihart, Bruce J., Mwakingwe, Agnes, Gabriel, Erin E., Decederfelt, Hope, Hobbs, Charlotte V., Rausch, Kelly M., Zhu, Daming, Muratova, Olga, Herrera, Raul, Scaria, Puthupparampil V., MacDonald, Nicholas J., Lambert, Lynn E., Zaidi, Irfan, Coelho, Camila H., Renn, Jonathan P., Wu, Yimin, Narum, David L., Duffy, Patrick E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2021
Materias:	Clinical Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011888/ https://www.ncbi.nlm.nih.gov/pubmed/33561016 http://dx.doi.org/10.1172/JCI146221

Ejemplares similares

Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission
por: Rausch, Kelly M., et al.
Publicado: (2023)

Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins
por: Singh, Kavita, et al.
Publicado: (2020)

Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230
por: Scaria, Puthupparampil V., et al.
Publicado: (2019)

Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose
por: Huang, Wei-Chiao, et al.
Publicado: (2020)

The Pfs230 N-terminal fragment, Pfs230D1+: expression and characterization of a potential malaria transmission-blocking vaccine candidate
por: Lee, Shwu-Maan, et al.
Publicado: (2019)

Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine
por: Singh, Susheel K., et al.
Publicado: (2021)

Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice
por: Coelho, Camila H., et al.
Publicado: (2019)

Rare Alleles and Signatures of Selection on the Immunodominant Domains of Pfs230 and Pfs48/45 in Malaria Parasites From Western Kenya
por: Ochwedo, Kevin O., et al.
Publicado: (2022)

Nanobodies against Pfs230 block Plasmodium falciparum transmission
por: Dietrich, Melanie H., et al.
Publicado: (2022)

Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum
por: Singh, Susheel K., et al.
Publicado: (2019)

Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages
por: Huang, Wei-Chiao, et al.
Publicado: (2022)

Development and Qualification of an Antigen Integrity Assay for a Plasmodium falciparum Malaria Transmission Blocking Vaccine Candidate, Pfs230
por: Miura, Kazutoyo, et al.
Publicado: (2022)

Identification of domains within Pfs230 that elicit transmission blocking antibody responses
por: Tachibana, Mayumi, et al.
Publicado: (2019)

Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment
por: Huang, Wei-Chiao, et al.
Publicado: (2020)

The Dynamics of Naturally Acquired Immune Responses to Plasmodium falciparum Sexual Stage Antigens Pfs230 & Pfs48/45 in a Low Endemic Area in Tanzania
por: Bousema, Teun, et al.
Publicado: (2010)

Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate
por: Radtke, Andrea J., et al.
Publicado: (2017)

Expression and purification optimization of an N-terminal Pfs230 transmission-blocking vaccine candidate
por: Lee, Shwu-Maan, et al.
Publicado: (2019)

Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
por: Wu, Yimin, et al.
Publicado: (2008)

Safety and Immunogenicity of Pfs25-EPA/Alhydrogel(®), a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults
por: Talaat, Kawsar R., et al.
Publicado: (2016)

Structural and immunological differences in Plasmodium falciparum sexual stage transmission-blocking vaccines comprised of Pfs25-EPA nanoparticles
por: MacDonald, Nicholas J., et al.
Publicado: (2023)

Profiling the Quality and Quantity of Naturally Induced Antibody Responses Against Pfs230 and Pfs48/45 Among Non-Febrile Children Living in Southern Ghana: A Longitudinal Study
por: Broni, Fermin K., et al.
Publicado: (2021)

Antibody responses to two new Lactococcus lactis-produced recombinant Pfs48/45 and Pfs230 proteins increase with age in malaria patients living in the Central Region of Ghana
por: Acquah, Festus K., et al.
Publicado: (2017)

A human antibody epitope map of the malaria vaccine antigen Pfs25
por: Shukla, Niharika, et al.
Publicado: (2023)

Plant-produced transmission blocking Plasmodium falciparum Pfs25 subunit and VLP based vaccine candidates
por: Musivchuk, Konstantin, et al.
Publicado: (2012)

Dynamics of anti-MSP3 and Pfs230 antibody responses and multiplicity of infection in asymptomatic children from southern Ghana
por: Amoah, Linda E., et al.
Publicado: (2018)

TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25
por: Thompson, Elizabeth A., et al.
Publicado: (2018)

N-Terminal Pfs230 Domain Produced in Baculovirus as a Biological Active Transmission-Blocking Vaccine Candidate
por: Lee, Shwu-Maan, et al.
Publicado: (2017)

Elucidating functional epitopes within the N-terminal region of malaria transmission blocking vaccine antigen Pfs230
por: Miura, Kazutoyo, et al.
Publicado: (2022)

A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle
por: Salinas, Nichole D., et al.
Publicado: (2023)

Design of a stabilized non-glycosylated Pfs48/45 antigen enables a potent malaria transmission-blocking nanoparticle vaccine
por: Dickey, Thayne H., et al.
Publicado: (2023)

Antibody targeting of a specific region of Pfs47 blocks Plasmodium falciparum malaria transmission
por: Canepa, Gaspar E., et al.
Publicado: (2018)

Potent transmission-blocking monoclonal antibodies from naturally exposed individuals target a conserved epitope on Plasmodium falciparum Pfs230
por: Ivanochko, Danton, et al.
Publicado: (2023)

Molecular Analysis of Pfs47-Mediated Plasmodium Evasion of Mosquito Immunity
por: Canepa, Gaspar E., et al.
Publicado: (2016)

Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer
por: Miura, Kazutoyo, et al.
Publicado: (2007)

Usage of Plant Food Supplements (PFS) for weight control in six European countries: results from the PlantLIBRA PFS Consumer Survey 2011-2012
por: Garcia-Alvarez, Alicia, et al.
Publicado: (2016)

Algae-Produced Pfs25 Elicits Antibodies That Inhibit Malaria Transmission
por: Gregory, James A., et al.
Publicado: (2012)

Effect of late-onset hemorrhagic cystitis on PFS after haplo-PBSCT
por: Yuan, Hailong, et al.
Publicado: (2021)

Translation, Adaptation and Validation of the Pandemic Fatigue Scale (PFS) in the Greek Language
por: Asimakopoulou, Evanthia, et al.
Publicado: (2022)

TTFields Prolonged the PFS of Epithelioid Glioblastoma Patient: A Case Report
por: Ding, Yuxuan, et al.
Publicado: (2023)

A Viral Vectored Prime-Boost Immunization Regime Targeting the Malaria Pfs25 Antigen Induces Transmission-Blocking Activity
por: Goodman, Anna L., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_onggq3fd9hlo5ll8ap9i7ti7eg